A pair of good-news items from Chimerix Inc. pushed the Durham, N.C.-based company’s stock (NASDAQ:CMRX) to $2.15, closing up 64 cents, or 42%, higher as backers reacted to near-term NDA plans for smallpox countermeasure brincidofovir (BCV) and the start of a phase II/III trial with dociparstat sodium (DSTAT) in COVID-19 patients with acute lung injury (ALI). CEO Mike Sherman said the […]

Amgen may be leading the race to develop a KRAS inhibitor, but its candidate hasn’t logged the same success in colon cancer as it has in lung cancer. Early data out of the annual meeting of the American Association for Cancer Research (AACR) suggest a different route to treating patients with KRAS-mutated colon cancer—including those […]

Updated interim data from an ongoing Phase I dose-escalation phase clinical study (NCT03748186) evaluating the folate receptor alpha (FRα) antibody-drug conjugate (ADC) STRO-002 (Sutro Biopharma) shows encouraging results.[1] The trial was designed to study the safety and anti-tumor activity results in heavily pre-treated patients with ovarian cancer. Folate receptor alpha or FRα is a glycosylphosphatidylinositol (GPI)-anchored membrane protein is overexpressed in solid […]